FluoRok Raises $30M for HF-Free Chemical Manufacturing

The specification for a battery electrolyte salt leaves little room for a supplier's creative interpretation. FluoRok is putting its inventiveness upstream, into the manufacturing route, while aiming to deliver the chemicals buyers already know how to use.

The Oxford, UK company announced a $30M (£22.8M) Series A financing on November 5, 2026, led by Orano Venture Fund, managed by Supernova Invest. The announced total includes approximately $1.3M (£1M) in Innovate UK grants, alongside investment intended to take hydrogen-fluoride-free fluorochemical production toward industrial scale.

For founders Gabriele Pupo and Véronique Gouverneur, the next assignment reaches beyond the chemistry developed at the University of Oxford. Demonstrator facilities and customer qualification will bring that work into the purchasing decisions of companies making batteries, pharmaceuticals and agrochemicals, where a new process still has to supply a dependable material.

What FluoRok's Series A will finance

FluoRok's financing is aimed at the practical work between pilot qualification and repeatable industrial production. The company plans demonstrator facilities for its reagents and lithium-ion battery electrolyte salts, a larger team, customer validation at scale and broader commercial partnerships. Its announcement reports completed pilot qualifications, while leaving the size and timing of future industrial output unspecified.

Bidra Innovation Ventures joined the round alongside returning investors Oxford Science Enterprises, BGF, Green Generation Fund, Volta Energy Technologies and the University of Oxford. EverQuest Capital Partners, CPI Enterprises, WS Investment and angel investors also participated. CPI's additional role as a scale-up partner gives the transaction an operating connection to the manufacturing work it finances.

The financing comes after earlier investment in the Oxford spinout. The University of Oxford's September 2024 account records a £7.7M round led by BGF alongside Green Generation Fund. The latest release reports $14M (£11M) in previous rounds and more than $13M (£10M) in public funding secured to date; those figures should remain separate because the announcement provides no reconciled cumulative funding ledger.

That distinction also applies to the new headline amount. Approximately $1.3M of the announced $30M comes from Innovate UK's Investor Partnerships programme, so describing the full total as fresh equity would overstate what the release establishes. The useful question for a supplier or industrial partner is where the combined financing takes production, particularly as the company moves into equipment and validation work.

Why removing HF changes the factory conversation

Fluorochemicals serve several established markets, but the conventional route starts with a demanding intermediate. FluoRok's technology explanation describes high-purity fluorspar reacting with sulfuric acid at high temperatures to produce hydrogen fluoride, or HF. The hazards of producing and handling HF influence the infrastructure and operating procedures required around the chemical.

FluoRok combines mechanical activation with base chemistry to bypass that stage. The company says its process can use lower-grade mineral fluoride and fluoride recovered from industrial waste streams, widening the potential raw-material base. It also describes the use of off-the-shelf industrial equipment, an important design choice for a business seeking to move chemistry beyond specialised laboratory setups.

These are consequential changes to propose to a manufacturer. A production route helps determine what needs to be purchased, handled and maintained before a saleable batch leaves the plant. A process that can avoid an especially hazardous intermediate could change those choices, although the announcement gives buyers no universal industrial cost guarantee or capacity commitment to price into an order today.

The product specification remains the connecting thread. FluoRok presents itself as a process innovator supplying established materials, rather than requiring customers to adopt an unfamiliar chemical. That gives the company a clear commercial proposition to investigate with customers: preserve the required material performance while reconsidering the production infrastructure behind it.

Familiar products, a different supplier proposition

FluoRok's initial markets include inorganic fluorides used in pharmaceutical and agrochemical applications, together with lithium hexafluorophosphate, or LiPF6, for lithium-ion battery electrolytes. Its solutions portfolio includes sodium fluoride, potassium fluoride and lithium fluoride. For these materials, the company identifies purity and moisture control as important to downstream performance and manufacturing yields.

A buyer assessing a new source consequently needs more than a persuasive account of the reaction. Customer validation connects a producer's process to the requirements of the application receiving its output. That helps explain why the planned demonstrators and at-scale qualification work belong together in the use-of-funds statement: manufacturing development and commercial adoption advance through many of the same conversations.

The technology page reports product validation by more than 10 partners across 8 countries and 3 continents, with battery electrolyte salts above 99.95% purity. Those are company-reported results. FluoRok has not identified the customers, contracted volumes or a fully operating industrial plant in this financing announcement, so the published validation claims should not be mistaken for a disclosed order book.

Competition therefore sits inside the supply decision as much as the chemical formula. Existing materials arrive with established manufacturing routes and supplier relationships; FluoRok is offering a different way to make them. The eventual buyer will weigh reliable specification, available volume and supply arrangements together, with the new chemistry earning its place through that ordinary industrial scrutiny.

An Oxford discovery moves into manufacturing relationships

FluoRok was founded in 2022, with Pupo bringing experience as an Oxford Chemistry postdoctoral researcher and Gouverneur contributing as a founder and director. Pupo remains CEO, founder and director on the current company leadership page. That continuity matters as a scientific enterprise takes on the additional disciplines of manufacturing, finance and commercial development.

The current team includes CBO Andrew Schwarz, CFO Joanna Dunne and VP of Manufacturing Marion Davies. Their roles make the scale-up assignment tangible: a chemical process must become an organisation capable of producing, qualifying and supplying material. The investment funds that transition while customer requirements continue to shape what counts as useful progress.

FluoRok also frames its manufacturing route as a way to support production closer to end markets. The geographic implication follows from its stated effort to reduce the infrastructure and feedstock constraints of conventional HF-based manufacturing. It remains a deployment opportunity, with the location, output and economics of future facilities still to be established through specific projects.

For battery and chemical manufacturers, that leaves an unusually concrete way to follow the company's development. The demonstrator is where the laboratory route encounters repeatability, production equipment and the customer's required material in the same place. As those facilities develop, FluoRok's prospective buyers will be looking for their specifications to survive the journey from an Oxford discovery into the next supply agreement.